Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population

American Journal of Hypertension

Volumn 22, Issue 12, 2009, Pages 1295-1302

  Van Rijn Bikker, Petra C ^a   Mairuhu, Gideon ^b   Van Montfrans, Gert A ^a   Sijbrands, Eric J G ^c   Zwinderman, Aeilko H ^a   Guchelaar, Henk Jan ^d   Koopmans, Richard P ^e  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE SYNTHASE; ALPHA ADDUCIN; ANGIOTENSINOGEN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; EPROSARTAN; HYDROCHLOROTHIAZIDE; LISINOPRIL; MEPIRODIPINE; NEBIVOLOL; SODIUM CHLORIDE COTRANSPORTER;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ENVIRONMENTAL FACTOR; ESSENTIAL HYPERTENSION; ETHNICITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; ETHNIC GROUPS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SURINAME;

EID: 70450221929     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.192     Document Type: Article

References (36)

1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004; 44:398-404.
2. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008-2013.
3. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914-921.
4. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health 2006; 27:465-490.
5. Materson BJ. Variability in response to antihypertensive drugs. Am J Med 2007; 120:S10-S20.
6. Staessen JA, Wang J, Bianchi G, Birkenhäger WH. Essential hypertension. Lancet 2003; 361:1629-1641.
7. Marteau JB, Zaiou M, Siest G, Visvikis-Siest S. Genetic determinants of blood pressure regulation. J Hypertens 2005; 23:2127-2143.
8. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, Benjamin N, Webster J, Ratcliffe P, O'Shea S, Papp J, Taylor E, Dobson R, Knight J, Newhouse S, Hooper J, Lee W, Brain N, Clayton D, Lathrop GM, Farrall M, Connell J; MRC British Genetics of Hypertension Study. Genome-wide mapping of human loci for essential hypertension. Lancet 2003; 361:2118-2123.
9. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 2002; 61:1047-1055.
10. Gill JS, Zezulka AV, Beevers DG, Davies P. Relation between initial blood pressure and its fall with treatment. Lancet 1985; 1:567-569.
11. Sumner DJ, Meredith PA, Howie CA, Elliott HL. Initial blood pressure as a predictor of the response to antihypertensive therapy. Br J Clin Pharmacol 1988; 26:715-720.
12. Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. A m J Hypertens 1998; 11:894-896.
13. Bühler FR, Bolli P, Kiowski W, Erne P, Hulthén UL, Block LH. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984; 77:36-42.
14. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998; 280:1168-1172.
15. Mackenzie IS, Brown MJ. Genetic profiling versus drug rotation in the optimisation of antihypertensive treatment. Clin Med 2002; 2:465-473.
16. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004; 141:614-627.
17. Kurland L, Lind L, Melhus H. Using genotyping to predict responses to anti-hypertensive treatment. Trends Pharmacol Sci 2005; 26:443-447.
18. Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005; 23:1311-1325.
19. Arnett DK, Claas SA, Glasser S P. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 2006; 44:107-118.
20. Schelleman H, Stricker BH, De Boer A, Kroon AA, Verschuren MW, Van Duijn CM, Psaty BM, Klungel OH. Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004; 64:1801-1816.
21. Agyemang C, Bindraban N, Mairuhu G, Montfrans G, Koopmans R, Stronks K; SUNSET (Surinamese in The Netherlands: Study on Ethnicity and Health) Study Group. Prevalence, awareness, treatment, and control of hypertension among Black Surinamese, South Asian Surinamese and White Dutch in Amsterdam, The Netherlands: the SUNSET study. J Hypertens 2005; 23:1971-1977.
22. Stronks K, Kulu-Glasgow I, Agyemang C. The utility of 'country of birth' for the classification of ethnic groups in health research: the Dutch experience. Ethn Health 2009; 14:1-14.
23. Hilgers KF, Langenfeld MR, Schlaich M, Veelken R, Schmieder RE. 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II. Circulation 1999; 100:1394-1399.
24. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992; 20:1433.
25. Filigheddu F, Troffa C, Glorioso N. Pharmacogenomics of essential hypertension: are we going the right way? Cardiovasc Hematol Agents Med Chem 2006; 4:7-15.
26. Efron B, Tibshirani R. An Introduction to the Bootstrap. Chapman & Hall: New York, NY, 1993.
27. Hoh J, Wille A, Zee R, Cheng S, Reynolds R, Lindpaintner K, Ott J. Selecting SNPs in two-stage analysis of disease association data: a model-free approach. Ann Hum Genet 2000; 64:413-417.
28. Mpio I, Laville M, Hadj-Aïssa A, Fauvel J P. Predicted creatinine clearance to evaluate glomerular filtration rate in black Caribbean subjects. Nephrol Dial Transplant 2003; 18:1307-1310.
29. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16:834-839.
30. Turner MJ, van Schalkwyk JM. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study. Am J Hypertens 2008; 21:85-91.
31. Marshall T. Misleading measurements: modeling the effects of blood pressure misclassification in a United States population. Med Decis Making 2006; 26:624-632.
32. Marshall T P. Blood pressure variability: the challenge of variation. Am J Hypertens 2008; 21:3-4.
33. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, Kjeldsen S, Lüscher T, Mallion JM, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, van Zwieten P, Waeber B, Williams B, Zanchetti A; ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21:1779-1786.
34. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 2005; 46:758-765.
35. Schelleman H, Klungel OH, Witteman JC, Hofman A, van Duijn CM, de Boer A, Stricker BH. The influence of the α-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. Eur J Hum Genet 2006; 14:860-866.
36. Suonsyrjä T, Hannila-Handelberg T, Fodstad H, Donner K, Kontula K, Hiltunen T P. Renin-angiotensin system and α-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. Am J Hypertens 2009; 22:169-175.